Blood tests like Lumipulse G p-tau217 accurately detect Alzheimer's pathology in Down syndrome patients, offering less invasive alternatives to brain scans and spinal taps. People with Down syndrome have over 90% lifetime risk of Alzheimer's due to genetic duplication causing amyloid buildup, yet were excluded from FDA-approved diagnostic tools.
Blood tests show promise for Alzheimer's detection in Down syndrome patients
People with Down syndrome face dramatically higher Alzheimer's incidence and mortality, with the disease being the leading cause of death in this population over age 35.